Teclistamab 

Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM)^[1].

Teclistamab (0.01-1000 nM, 48 h) induces T cell–mediated cytotoxicity with the EC₅₀ values of 0.15 nM in H929 cells, 0.06 nM in MM.1R cell lines, and 0.45 nM in RPMI 8226 cell lines, respectively^[1].
Teclistamab (0.01-1000 nM, 48 h) can bind CD138 ⁺ human BM monocytes in a dose-dependent manner and induces cytotoxicity of human BM monocytes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Teclistamab (i.v., 0.1-1 μg, once every 2 days) has anti-tumor activity at high doses in female NSG (NOD/SCID/γc^−/−) mice with H929 cells model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2119595-80-9

Liquid

Colorless to light yellow

[Teclistamab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kodandaram Pillarisetti, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020 Sep 22;4(18):4538-4549.  [Content Brief]